Skip NavigationSkip to Content
Return Return to Search Results

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants

  1. Author:
    Chen, Zhaochun
    Zhang, Peng
    Matsuoka, Yumiko
    Tsybovsky,Yaroslav
    West, Kamille
    Santos, Celia
    Boyd, Lisa F
    Nguyen, Hanh
    Pomerenke, Anna
    Stephens,Tyler
    Olia, Adam S
    Zhang, Baoshan
    De Giorgi, Valeria
    Holbrook, Michael R
    Gross, Robin
    Postnikova, Elena
    Garza, Nicole L
    Johnson, Reed F
    Margulies, David H
    Kwong, Peter D
    Alter, Harvey J
    Buchholz, Ursula J
    Lusso, Paolo
    Farci, Patrizia

  2. Author Address

    Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: zchen@niaid.nih.gov., Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA., Molecular Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, National Institutes of Health, Frederick, MD, USA., SARS-CoV-2 Virology Core, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: pfarci@niaid.nih.gov.,
    1. Year: 2022
    2. Date: Sep 30
    3. Epub Date: 2022 09 30
  2. Journal: Cell Reports
    1. 41
    2. 5
    3. Pages: 111528
  4. Type of Article: Article
  5. Article Number: 111528
  1. Abstract:

    The emergence and global spread of the SARS-CoV-2 Omicron variants, which carry an unprecedented number of mutations, raise serious concerns due to the reduced efficacy of current vaccines and resistance to therapeutic antibodies. Here, we report the generation and characterization of two potent human monoclonal antibodies, NA8 and NE12, against the receptor-binding domain of the SARS-CoV-2 spike protein. NA8 interacts with a highly conserved region and has a breadth of neutralization with picomolar potency against the Beta variant and the Omicron BA.1 and BA.2 sublineages and nanomolar potency against BA.2.12.1 and BA.4. Combination of NA8 and NE12 retains potent neutralizing activity against the major SARS-CoV-2 variants of concern. Cryo-EM analysis provides the structural basis for the broad and complementary neutralizing activity of these two antibodies. We confirm the in vivo protective and therapeutic efficacies of NA8 and NE12 in the hamster model. These results show that broad and potent human antibodies can overcome the continuous immune escape of evolving SARS-CoV-2 variants. Copyright © 2022. Published by Elsevier Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.celrep.2022.111528
  3. PMID: 36302375
  4. PMCID: PMC9554601
  5. View record in Web of Science®
  6. WOS: 000884847000004
  7. PII : S2211-1247(22)01384-5

Library Notes

  1. Fiscal Year: FY2022-2023
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel